governmentUnited KingdomAnnounce plans to participate in mRNA cancer vaccine research in collaboration with a German biotech pharmaceutical company with signing of agreement
Although mRNA or messenger ribonucleic acid technology is new. But after the success of using this technology to produce a COVID-19 vaccine with Pfizer Scientists then moved on to using the same technology in studies of vaccines for use in cancer patients.
It is predicted that by the end of 2030 there will be cancer patients both from actual treatment. and in the experimental process to obtaincancer vaccineIt has been customized for up to 10,000 people, but because cancer is a complex disease patients may need multiple doses of the vaccine to stimulate the immune system to stay alert.
Ugur Sahin, founder and CEO of biotech company The German pharmaceutical manufacturer said that the project will be aimed at cancer immunotherapy. Various infectious disease vaccines it hopes to target bioentech in the UK Develop vaccines using technology the company has been researching and developing for more than 20 years.
The steps after this is the selection of trial participants and place to use for testing To have the vaccine ready for use in the second half of 2023, some of the patients participating in the trial will be patients who have previously had cancer and are already been taken care of. And they hope the vaccine will help prevent their cancer from coming back.
In addition, Bioentech will open a research and development center. There will be around 70 staff stationed in Cambridge. It will also establish its regional headquarters in London.
mRNA technology, effective therapeutic option for cancer
Scientists say mRNA vaccines could be a game changer in the fight against many diseases because they can trigger immune responses. By injecting genetic molecules that code for key parts of the pathogen into human cells. Additionally, this vaccine takes less time to develop than traditional vaccines.
Dr Ian Falks, Executive Director of Cancer Research and Innovation UK He has identified mRNA vaccines as one of the most exciting research developments and developments. released during the COVID pandemic and it is highly probable that This vaccine can become a good alternative to cancer treatment. It would not have been possible without the collaboration. and an enabling environment for efficient UK research and development. which greatly supports the work of the staff
However, governments should be aware of issues that could hamper processes. such as understaffing and cancer patients due to the epidemic Making staff work harder And there may not be enough time to support medical trials. As a result, the process of finding new treatments is further delayed. There were also concerns expressed by activists who came out early to appeal to the British government. About a cancer vaccine that will be produced for use in the future if the trial is successful To ensure that the price of the vaccine that will be released is not too expensive for general public access. Because it doesn’t matter how effective the drug is If patients who really need treatment can’t buy it and use It wouldn’t help.
Author: Ajumma Opal
